{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:23:57Z","timestamp":1787664237640,"version":"build-2736575974"},"reference-count":29,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Clinical decision making in Acute Myeloid Leukemia (AML) critically relies on rapid genomic characterization. To better understand the AML diagnostic landscape in Canada, the Canadian Leukemia Study Group (CLSG) conducted a survey of laboratory hematology leadership (n = 18) at 16 laboratories across 10 provinces, administered using Google Forms in September 2024. Nearly all surveyed sites were equipped to deliver a full suite of testing platforms through existing on-site infrastructure or laboratory partnerships. Reporting practices varied in terms of genomic integration into bone marrow results and the use of AML classification systems. Turn-around-time (TAT) targets were predominantly determined through internal institutional consensus (62%) or recommendations by provincial cancer agencies\/international groups (44%). TAT reduction was a top priority for 56% of laboratories, suggesting timely biomarker results to be an active area for improvement. Various treatment-determining biomarkers were frequently assessed as rapid-tests (defined as a 5-day TAT), including FLT3-ITD (69%), FLT3-TKD (56%), and NPM1 (56%), while others such as IDH1 and TP53 were rapid at a limited number of laboratories. Respondents demonstrated a strong shared interest in joint projects such as the validation of AML measurable residual disease (MRD) assays (56%). There was also unanimous support for establishing CLSG AML laboratory consensus guidelines. This survey documents the current state of Canadian AML laboratories and provides a foundation for future shared development projects.<\/jats:p>","DOI":"10.3390\/curroncol33090505","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:57:17Z","timestamp":1787662637000},"page":"505","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Charting the Future of Canadian Adult Acute Myeloid Leukemia (AML) Laboratory Testing: A Canadian Leukemia Study Group Current State Mapping of Diagnostic AML Laboratory Practice"],"prefix":"10.3390","volume":"33","author":[{"given":"Tina Yu Xuan","family":"Luo","sequence":"first","affiliation":[{"name":"Biological Sciences Platform, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sila","family":"Usta","sequence":"additional","affiliation":[{"name":"Biological Sciences Platform, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada"},{"name":"Division of Hematological Pathology, Department Laboratory Medicine and Molecular Diagnostics, Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McGinnis","sequence":"additional","affiliation":[{"name":"Vancouver General Hospital, University of British Columbia, Vancouver, BC V5Z 1M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5164-5309","authenticated-orcid":false,"given":"Cheryl A.","family":"Mather","sequence":"additional","affiliation":[{"name":"Molecular Pathology (North Sector), Alberta Precision Laboratories, Edmonton, AB T6G 2B7, Canada"},{"name":"Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 1C9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2911-8631","authenticated-orcid":false,"given":"Julie","family":"Bergeron","sequence":"additional","affiliation":[{"name":"CEMTL Installation Maisonneuve-Rosemont, University of Montreal, Montreal, QC H1T 2M4, Canada"},{"name":"The Canadian Leukemia Study Group\/Groupe Canadiene D\u2019\u00e9tude sur la Leuc\u00e9mie (CLSG\/GCEL), Toronto, ON M4N 1A7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2278-9950","authenticated-orcid":false,"given":"Tanya","family":"Gillan","sequence":"additional","affiliation":[{"name":"Department of Pathology Central Zone, Nova Scotia Health, Halifax, NS B3H 1V8, Canada"},{"name":"Department of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-9339","authenticated-orcid":false,"given":"Etienne","family":"Mahe","sequence":"additional","affiliation":[{"name":"Departments of Pathology & Laboratory Medicine, and Division of Hematology & Hematological Malignancies, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada"},{"name":"Division of Hematology & Molecular Pathology Programme, Alberta Precision Laboratories, Calgary, AB T2N 2T9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Mario","family":"Capo-Chichi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"},{"name":"Division of Clinical Laboratory Genetics, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2302-6145","authenticated-orcid":false,"given":"Philip","family":"Berardi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Manitoba, Winnipeg, MB R3E 3P5, Canada"},{"name":"Diagnostic Services, Shared Health, Winnipeg, MB R3C 0C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doha","family":"Itani","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada"},{"name":"Molecular Diagnostics and Cytogenetics, Saint John Regional Hospital, Horizon Health, Saint John, NB E2L 4L2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Rajput","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Newfoundland Health Services, St John\u2019s, NL A1B 3V6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0737-3603","authenticated-orcid":false,"given":"Benjamin","family":"Chin-Yee","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, Canada"},{"name":"Department of Pathology and Laboratory Medicine, and Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Yu","family":"Han","sequence":"additional","affiliation":[{"name":"Laboratory Medicine, Memorial University, St. John\u2019s, NL A1B 3V6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darci T.","family":"Butcher","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada"},{"name":"Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences and St Joseph\u2019s Healthcare, Hamilton, ON L8N 4A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Fesser","sequence":"additional","affiliation":[{"name":"Transfusion Medicine and Laboratory Hematology, Queen Elizabeth Hospital, Health PEI, Charlottetown, PE C1A 8T5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"DeCoteau","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Quest","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen\u2019s University, Kingston Health Sciences Centre, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7952-2279","authenticated-orcid":false,"given":"Elizabeth","family":"McCready","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada"},{"name":"Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences and St Joseph\u2019s Healthcare, Hamilton, ON L8N 4A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7943-9099","authenticated-orcid":false,"given":"Hubert","family":"Tsui","sequence":"additional","affiliation":[{"name":"Biological Sciences Platform, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada"},{"name":"Division of Hematological Pathology, Department Laboratory Medicine and Molecular Diagnostics, Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"},{"name":"The Canadian Leukemia Study Group\/Groupe Canadiene D\u2019\u00e9tude sur la Leuc\u00e9mie (CLSG\/GCEL), Toronto, ON M4N 1A7, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"},{"name":"Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1016\/S2352-3026(22)00167-3","article-title":"Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia","volume":"9","author":"Short","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_4","first-page":"e70456","article-title":"Frailty in Patients with Hematologic Malignancies and Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review","volume":"9","author":"Bakken","year":"2026","journal-title":"Cancer Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","article-title":"Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)","volume":"26","author":"Wysota","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 update on MRD in acute myeloid leukemia: A consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2026","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/s41375-024-02275-x","article-title":"Recommendations from the AML molecular MRD expert advisory board","volume":"38","author":"Scott","year":"2024","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Longo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/bloodadvances.2020003806","article-title":"Impact of treatment delay in acute myeloid leukemia revisited","volume":"5","author":"Juliusson","year":"2021","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bjh.16360","article-title":"The power and potential of integrated diagnostics in acute myeloid leukaemia","volume":"188","author":"Haferlach","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_12","unstructured":"(2026, June 01). The Canadian Leukemia Study Group\/Groupe Canadiene D\u2019\u00e9tude Sur la Leuc\u00e9mie (CLSG\/GCEL). Available online: https:\/\/clsg.ca\/."},{"key":"ref_13","unstructured":"(2026, August 02). Assessment Framework for Biomarkers Used in Cancer Care. Available online: https:\/\/www.cda-amc.ca\/assessment-framework-biomarkers-used-cancer-care."},{"key":"ref_14","unstructured":"Vakiti, A., Reynolds, S.B., and Mewawalla, P. (2026). Acute Myeloid Leukemia, StatPearls."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1182\/bloodadvances.2025016399","article-title":"Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML","volume":"9","author":"Montesinos","year":"2025","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/bloodadvances.2024013685","article-title":"Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy","volume":"8","author":"Hoff","year":"2024","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood.2024026232","article-title":"Menin inhibitors in the treatment of acute myeloid leukemia","volume":"145","author":"Huls","year":"2025","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jmoldx.2026.01.002","article-title":"Technical Validation and Prospective Clinical Utility of Optical Genome Mapping in Acute Leukemia Workup","volume":"28","author":"Parlow","year":"2026","journal-title":"J. Mol. Diagn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_21","unstructured":"Acute Leukemia Working Group Pathology and Laboratory Medicine Program (2026, August 01). Acute Leukemia Consensus Pathology Recommendations for Diagnosis and Monitoring; Ontario Health, Cancer Care Ontario, Guidelines & Advice March 2026. Available online: https:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer\/80331."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10410","DOI":"10.3390\/curroncol30120759","article-title":"The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus","volume":"30","author":"Bergeron","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11899-020-00593-2","article-title":"Choosing Wisely(R) in Hematology: Have We Made a Difference?","volume":"15","author":"Hilal","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood.2026033569","article-title":"ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia","volume":"148","author":"Hourigan","year":"2026","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00277-024-05639-6","article-title":"Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation","volume":"103","author":"Lucero","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101533","DOI":"10.1016\/j.beha.2023.101533","article-title":"Cytogenetics and genomics of acute myeloid leukemia","volume":"37","author":"Snaith","year":"2024","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.26587","article-title":"Optical genome mapping for structural variation analysis in hematologic malignancies","volume":"97","author":"Smith","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Schuh, A.C., Brandwein, J., Elsawy, M., Sanford, D., and Leber, B. (2026). Controversies in the Management of AML in Older Patients: A Canadian Perspective. Curr. Oncol., 33.","DOI":"10.3390\/curroncol33070431"},{"key":"ref_29","unstructured":"(2025). Reimbursement Recommendations. Quizartinib (Vanflyta). Can. J. Health Technol., 5, 4."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/505\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:08:17Z","timestamp":1787663297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090505"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090505","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}